Literature DB >> 10468290

Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.

N J Curtin1, K J Bowman, R N Turner, B Huang, P J Loughlin, A H Calvert, B T Golding, R J Griffin, D R Newell.   

Abstract

Dipyridamole has been shown to enhance the in vitro activity of antimetabolite anticancer drugs through the inhibition of nucleoside transport. However, the clinical potential of dipyridamole has not been realized because of the avid binding of the drug to the plasma protein alpha1-acid glycoprotein (AGP). Dipyridamole analogues that retain potent nucleoside transport inhibitory activity in the presence of AGP are described and their ability to enhance the growth inhibitory and cytotoxic effects of thymidylate synthase (TS) inhibitors has been evaluated. Three dipyridamole analogues (NU3026, NU3059 and NU3060) were shown to enhance the growth inhibitory activity of the TS inhibitor CB3717 and block thymidine rescue in L1210 cells. The extent of potentiation at a fixed analogue concentration (10 microM) was related to the potency of inhibition of thymidine uptake. A further analogue, NU3076, was identified, which was more potent than dipyridamole with a Ki value for inhibition of thymidine uptake of 0.1 microM compared to 0.28 microM for dipyridamole. In marked contrast to dipyridamole, inhibition of thymidine uptake by NU3076 was not significantly affected by the presence of AGP (5 mg ml(-1)). NU3076 and dipyridamole produced equivalent potentiation of the cytotoxicity of the non-classical antifolate TS inhibitor, nolatrexed, in L1210 cells with both compounds significantly reducing the LC90, by > threefold in the absence of salvageable thymidine. Thymidine rescue of L1210 cells from nolatrexed cytotoxicity was partially blocked by both 1 microM NU3076 and 1 microM dipyridamole. NU3076 also caused a significant potentiation of FU cytotoxicity in L1210 cells. These studies demonstrate that nucleoside transport inhibition can be maintained in the absence of AGP binding with the dipyridamole pharmacophore and that such analogues can enhance the cytotoxicity of TS inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468290      PMCID: PMC2363125          DOI: 10.1038/sj.bjc.6690591

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

Review 1.  Modulation of cytotoxic drug activity by dipyridamole.

Authors:  H J Schmoll; A Harstrick; C H Köhne-Wömpner; C Schöber; H Wilke; H Poliwoda
Journal:  Cancer Treat Rev       Date:  1990-12       Impact factor: 12.111

2.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

3.  A rapid-mixing technique to measure transport in suspended animal cells: applications to nucleoside transport in Novikoff rat hepatoma cells.

Authors:  R M Wohlhueter; R Marz; J C Graff; P G Plagemann
Journal:  Methods Cell Biol       Date:  1978       Impact factor: 1.441

4.  A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

Authors:  T R Jones; A H Calvert; A L Jackman; S J Brown; M Jones; K R Harrap
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

5.  Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line.

Authors:  C R Crawford; D H Patel; C Naeve; J A Belt
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

6.  Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs.

Authors:  M Griffiths; N Beaumont; S Y Yao; M Sundaram; C E Boumah; A Davies; F Y Kwong; I Coe; C E Cass; J D Young; S A Baldwin
Journal:  Nat Med       Date:  1997-01       Impact factor: 53.440

Review 7.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.

Authors:  Y M Rustum; A Harstrick; S Cao; U Vanhoefer; M B Yin; H Wilke; S Seeber
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

8.  Dipyridamol kinetics.

Authors:  C Mahony; K M Wolfram; D M Cocchetto; T D Bjornsson
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

9.  AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies.

Authors:  S Webber; C A Bartlett; T J Boritzki; J A Hillard; E F Howland; A L Johnston; M Kosa; S A Margosiak; C A Morse; B V Shetty
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 10.  Nucleoside salvage and resistance to antimetabolite anticancer agents.

Authors:  M Fox; J M Boyle; A R Kinsella
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

View more
  1 in total

1.  Dipyridamole prevents triple-negative breast-cancer progression.

Authors:  Daniela Spano; Jean-Claude Marshall; Natascia Marino; Daniela De Martino; Alessia Romano; Maria Nunzia Scoppettuolo; Anna Maria Bello; Valeria Di Dato; Luigi Navas; Gennaro De Vita; Chiara Medaglia; Patricia S Steeg; Massimo Zollo
Journal:  Clin Exp Metastasis       Date:  2012-07-04       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.